Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 68,9 M
EBIT 2017 -4,67 M
Net income 2017 -13,8 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 88,4 M
EBIT 2018 0,71 M
Net income 2018 -8,41 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 3,74x
EV / Sales2018 2,90x
Capitalization 186 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
03/06Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
01/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Regulation FD Disclosure
01/10 TELIGENT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
01/03 Teligent, Inc. to Present at the J.P. Morgan 36th Annual Healthcare Conferenc..
2017 TELIGENT : Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotio..
2017 Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrat..
2017 TELIGENT : Announces FDA Approval of Erythromycin Topical Solution USP, 2%
2017 Teligent, Inc. Announces FDA Approval of Erythromycin Topical Solution USP, 2..
2017 TELIGENT INC : Featured Company News - FDA Approved Teligent's Betamethasone Dip..
2017 TELIGENT : Announces FDA Approval of Betamethasone Dipropionate Ointment USP (Au..
2017 Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Ointment ..
More news
Sector news : Pharmaceuticals - NEC
08:31p Wall St. touches records as Senate deals to end shutdown
08:22p Canada's small financial firms get buzz from weed stocks
07:59p Big Drugmakers Pay Big Prices for Promising Biotechs
06:16p Dealmaking drives European stocks as equity melt-up continues
06:14p UK stocks decline as gamblers stumble on government clampdown worries
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,53 $
Spread / Average Target 59%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI186
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132